https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-17 / Ann. Oncol. 2006 Apr;17(4):563-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-17 / Ann. Oncol. 2006 Apr;17(4):563-702006-01-17 00:00:002019-02-15 09:19:51Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-09 / Proc. Natl. Acad. Sci. U.S.A. 2006 Jan;103(3):738-43
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-09 / Proc. Natl. Acad. Sci. U.S.A. 2006 Jan;103(3):738-432006-01-09 00:00:002019-02-15 09:15:17Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-05 / Breast Cancer Res. 2006;8(1):101
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-05 / Breast Cancer Res. 2006;8(1):1012006-01-05 00:00:002019-02-15 08:44:41Dendritic cell defects in patients with cancer: mechanisms and significance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / J Gene Med 2006 Jan;8(1):3-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / J Gene Med 2006 Jan;8(1):3-172006-01-01 00:00:002019-02-15 09:15:18From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Adv. Immunol. 2006;90:243-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Adv. Immunol. 2006;90:243-952006-01-01 00:00:002019-02-15 09:19:49Immunity to melanoma antigens: from self-tolerance to immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Biol. Pharm. Bull. 2006 Jan;29(1):100-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Biol. Pharm. Bull. 2006 Jan;29(1):100-42006-01-01 00:00:002019-02-15 09:19:53Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Curr. Pharm. Des. 2006;12(7):807-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Curr. Pharm. Des. 2006;12(7):807-172006-01-01 00:00:002019-02-15 09:24:18Immunotherapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Cytotherapy 2006;8(3):277-89
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Cytotherapy 2006;8(3):277-892006-01-01 00:00:002019-02-15 08:51:01Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Leuk. Lymphoma 2006 Jan;47(1):29-37
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Leuk. Lymphoma 2006 Jan;47(1):29-372006-01-01 00:00:002019-02-15 08:51:02Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / J. Immunother. 2006 Jan-Feb;29(1):67-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / J. Immunother. 2006 Jan-Feb;29(1):67-772006-01-01 00:00:002006-01-01 00:00:00Quick generation of fully mature dendritic cells from monocytes with OK432, low-dose prostanoid, and interferon-alpha as potent immune enhancers
